ELTX.US Elicio Therapeutics Inc.

Healthcare Pharmaceuticals USA Stocks
1.50 USD
Close of Nov 14, 2026
1.25 16.00
Market cap
USD 42.5M
P/E
-
P/B
2.34x
ROE
-198.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ELTX.US undervalued?

Graham number

The Graham number of Elicio Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Elicio Therapeutics Inc. fundamental analysis

No fundamental analysis for Elicio Therapeutics Inc. yet.

Elicio Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Elicio Therapeutics Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolo…

Full company profile